Assembly Biosciences
ASMB
65 hedge funds and large institutions have $78.8M invested in Assembly Biosciences in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 25 increasing their positions, 25 reducing their positions, and 29 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 25
1.41% less ownership
Funds ownership: 5.62% → 4.21% (-1.4%)
16% less call options, than puts
Call options by funds: $875K | Put options by funds: $1.04M
25% less capital invested
Capital invested by funds: $105M → $78.8M (-$26.3M)
29% less funds holding
Funds holding: 91 → 65 (-26)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
90% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 29
Top Buyers
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$1.24M |
| 2 |
EP
Eversept Partners
New York
|
+$1.22M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$497K |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$407K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$349K |
Top Sellers
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$8.18M |
| 2 |
Two Sigma Investments
New York
|
-$2.51M |
| 3 |
VVA
Vida Ventures Advisors
Boston,
Massachusetts
|
-$1.49M |
| 4 |
Two Sigma Advisers
New York
|
-$1.43M |
| 5 |
Millennium Management
New York
|
-$862K |
ASMB Hedge Fund Activity: Q3 2021 in Review
65 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q3 2021, worth a combined $78.8M — down 25% from $105M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ASMB and 3 opened new positions — a net loss of 26 holders — while 25 trimmed existing stakes and 25 added.
The largest buyer was Candriam SCA, adding an estimated $1.24M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $8.18M sold.
- 65 institutional investors held Assembly Biosciences (ASMB) as of Q3 2021, down from 91 in Q2 2021.
- Funds reported $78.8M of Assembly Biosciences stock for Q3 2021, down 25% quarter-over-quarter.
- 3 funds opened new Assembly Biosciences positions in Q3 2021 and 29 closed out, a net change of -26 holders.
- The largest Assembly Biosciences buyer in Q3 2021 was Candriam SCA, an estimated $1.24M added.
- The largest Assembly Biosciences seller in Q3 2021 was Baker Bros. Advisors, an estimated $8.18M sold.
Based on aggregated 13F filings for Q3 2021.